No abstract available
MeSH terms
-
Adenocarcinoma / drug therapy*
-
Adenocarcinoma / mortality
-
Adenocarcinoma / pathology
-
Adenocarcinoma / radiotherapy
-
Adenocarcinoma / surgery
-
Androgen Antagonists / therapeutic use*
-
Antineoplastic Agents, Hormonal / therapeutic use*
-
Chemotherapy, Adjuvant
-
Clinical Trials as Topic
-
Combined Modality Therapy
-
Disease Progression
-
Disease-Free Survival
-
Drug Administration Schedule
-
Estrogens / therapeutic use
-
Gonadotropin-Releasing Hormone / analogs & derivatives
-
Gonadotropin-Releasing Hormone / therapeutic use
-
Humans
-
Male
-
Multicenter Studies as Topic
-
Neoadjuvant Therapy
-
Neoplasms, Hormone-Dependent / drug therapy*
-
Neoplasms, Hormone-Dependent / mortality
-
Neoplasms, Hormone-Dependent / pathology
-
Neoplasms, Hormone-Dependent / surgery
-
Orchiectomy
-
Palliative Care
-
Prostatectomy
-
Prostatic Neoplasms / drug therapy*
-
Prostatic Neoplasms / mortality
-
Prostatic Neoplasms / pathology
-
Prostatic Neoplasms / radiotherapy
-
Prostatic Neoplasms / surgery
-
Survival Analysis
-
Testosterone*
-
Treatment Outcome
Substances
-
Androgen Antagonists
-
Antineoplastic Agents, Hormonal
-
Estrogens
-
Gonadotropin-Releasing Hormone
-
Testosterone